PARI recognizes that the future of aerosol aerosol
An aerosol is a colloid of fine solid particles or liquid droplets, in air or another gas. therapies lies in the combined optimization of drug formulation and device platform - a core competency of PARI Pharma.
PARI Pharma is part of the global network of PARI Worldwide companies. The focus of PARI Pharma is the optimization of Advanced Aerosol Aerosol
An aerosol is a colloid of fine solid particles or liquid droplets, in air or another gas. Delivery platforms, such as eFlow Technology, with new liquid medications. The goal is to produce extremely short and effective treatments that lead to increased patient adherence, disease symptom control, and "improved" quality of life for patients.
By optimizing drug and device under one roof, we increase the speed of development for our pharmaceutical partners. Our projects include the re-invention of existing medications and the development of new medications. We are currently working on therapies for both the lower (pulmonary) and upper (sinus, nasal) respiratory pathways with targeted and systemic treatments.
Our Core Competencies include:
- aerosol aerosol
An aerosol is a colloid of fine solid particles or liquid droplets, in air or another gas. science
- business development
- fluid dynamics
- industrial design
- intellectual property
- device manufacturing
- pharmaceutical development
- clinical development
- project management
- quality management
- regulatory affairs
PARI Pharma continues PARI's tradition of developing high quality, technologically-advanced devices that can be mass produced for worldwide nebulized treatments.